First Quarter 2018 Investor Presentation
Investor Presentation
First three months of 2018
Slide 84
Phase 3a programme STEP and CV outcomes study SELECT
with semaglutide 2.4 mg in obesity to be initiated
Semaglutide in obesity phase 3a programme,
STEP, expected to include ~4,500 patients¹
2018
2019
2020
Cardiovascular outcomes study, SELECT,
planned for semaglutide in obesity
STEP 1: Weight loss
1,950 patients, 68 weeks
STEP 2: T2D non-insulin patients
1,200 patients, 68 weeks
STEP 3: Maximising weight loss
600 patients, 68 weeks
STEP 4: Maintained weight loss
900 patients, 68 weeks
H
Expected phase 3a programme completion: 2020
Semaglutide 2.4 mg sc QW
~17,500 people
with obesity¹
Placebo
Event-driven
Completion: Pre-defined number of events
1 Inclusion criteria: Male or female, age ≥18 years, BMI: ≥30 kg/m² or ≥27 kg/m² and ≥1 comorbidity
Note: All treatment arms are adjunct to diet and exercise
CV: Cardiovascular; T2D: Type 2 diabetes
1 Inclusion criteria: Male or female >45 years, BMI >27 kg/m², myocardial infarction or
stroke >60 days, HbA1c <6.5%
QW: Once-weekly; sc: Subcutaneous
novo nordiskView entire presentation